The development of technologies to generate MAbs created considerable excitement in oncology because of their potential use in tumor therapy. The use of agonistic monoclonal antibodies against certain targets have emerged as one of the most effective ways to boost immune responses against infectious agents or to fight cancer. Creative Biolabs is specialized in new agonistic antibody discovery.
Receptor agonism is a key step in the transmission of signals from the outside to the inside of a cell. The agonist activity can occur when the antibody binds the receptor in a manner that mimics the binding of the natural ligand, resulting in antibody-mediated downstream signaling or agonism. Antibody-mediated agonist activity can occur when the two FAb arms of an IgG each bind to a halfreceptor of a homodimeric receptor pair and cause the receptors to dimerize, or cross-link, in a way that mimics the activity of the natural ligand. There are currently at least 11 MAbs in clinical trials that are intended to function as receptor agonists.
Creative Biolabs employs phage-display technology to discover new agonist antibodies. Generally, either an immunized phage display library or a naive library will be used for antibody isolation on the recombinant extracellular domains (ECD) of the receptors. Antibodies specific for the receptor ECDs are detected by phage ELISA and the different scFv antibodies are further screened for agonism in some cell-based assays. With extensive experience in the field, Creative Biolabs has successfully isolated agonist antibodies to a panel of receptors, such as the TNF receptor superfamily, CD28, CD40, PD1, CD137 and so on.